RT Journal Article
SR Electronic
T1 Evolutionary and phenotypic characterization of spike mutations in a new SARS-CoV-2 Lineage reveals two Variants of Interest
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21253075
DO 10.1101/2021.03.08.21253075
A1 Paula Ruiz-Rodriguez
A1 Clara Francés-Gómez
A1 Álvaro Chiner-Oms
A1 Mariana G. López
A1 Santiago Jiménez-Serrano
A1 Irving Cancino-Muñoz
A1 Paula Ruiz-Hueso
A1 Manuela Torres-Puente
A1 Maria Alma Bracho
A1 Giuseppe D’Auria
A1 Llúcia Martinez-Priego
A1 Manuel Guerreiro
A1 Marta Montero-Alonso
A1 María Dolores Gómez
A1 José Luis Piñana
A1 SeqCOVID-SPAIN consortium
A1 Fernando González-Candelas
A1 Iñaki Comas
A1 Alberto Marina
A1 Ron Geller
A1 Mireia Coscolla
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.08.21253075.abstract
AB Molecular epidemiology of SARS-CoV-2 aims to monitor the appearance of new variants with the potential to change the virulence or transmissibility of the virus. During the first year of SARS-CoV-2 evolution, numerous variants with possible public health impact have emerged. We have detected two mutations in the Spike protein at amino acid positions 1163 and 1167 that have appeared independently multiple times in different genetic backgrounds, indicating they may increase viral fitness. Interestingly, the majority of these sequences appear in transmission clusters, with the genotype encoding mutations at both positions increasing in frequency more than single-site mutants. This genetic outcome that we denote as Lineage B.1.177.637, belongs to clade 20E and includes 12 additional single nucleotide polymorphisms but no deletions with respect to the reference genome (first sequence in Wuhan). B.1.177.637 appeared after the first wave of the epidemic in Spain, and subsequently spread to eight additional countries, increasing in frequency among sequences in public databases. Positions 1163 and 1167 of the Spike protein are situated in the HR2 domain, which is implicated in the fusion of the host and viral membranes. To better understand the effect of these mutations on the virus, we examined whether B.1.177.637 altered infectivity, thermal stability, or antibody sensitivity. Unexpectedly, we observed reduced infectivity of this variant relative to the ancestral 20E variant in vitro while the levels of viral RNA in nasopharyngeal swabs did not vary significantly. In addition, we found the mutations do not impact thermal stability or antibody susceptibility in vaccinated individuals but display a moderate reduction in sensitivity to neutralization by convalescent sera from early stages of the pandemic. Altogether, this lineage could be considered a Variant of Interest (VOI), we denote VOI1163.7. Finally, we detected a sub-cluster of sequences within VOI1163.7 that have acquired two additional changes previously associated with antibody escape and it could be identified as VOI1163.7.V2. Overall, we have detected the spread of a new Spike variant that may be advantageous to the virus and whose continuous transmission poses risks by the acquisition of additional mutations that could affect pre-existing immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Instituto de Salud Carlos III project COV20/00140 and COV20/00437, Spanish National Research Council project CSIC-COV19-021 and CSIC-COVID19-082, and the Generalitat Valenciana (SEJI/2019/011 and Covid_19-SCI). Action co-financed by the European Union through the Operational Program of the European Regional Development Fund (ERDF) of the Valencian Community 2014-2020. M.C. and R.G. are supported by Ramon y Cajal program from Ministerio de Ciencia. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sequencing of the samples has been approved by the ethics committee: Comite Etico de Investigacion de Salud Publica y Centro Superior de Investigacion en Salud Publica (CEI DGSP-CSISP) Number 20200414/05. All samples from Hospital Universitario y Politecnico La Fe de Valencia were collected after informed written consent and the project has been approved by the ethical committee and institutional review board (registration number 2020-123-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to this manuscript is available as supplemental material, and code can be found at https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2. The analysis pipeline used to map and analyze the sequences is available at https://gitlab.com/fisabio-ngs/sars-cov2-mapping https://github.com/PathoGenOmics/B.1.177.637_SARS-CoV-2 https://gitlab.com/fisabio-ngs/sars-cov2-mapping